Full-year results were marginally ahead of the July trading update. Revenue growth (10%), albeit at the lower end of target range, was affected by lower UK growth (+1%) but international markets (+19%) now account for 51% of revenues and EBITDA rose 16%. Clarity from the US FDA with regards the regulatory process for a high-level disinfectant has been received, and the revised process will delay the filing by six months. We still expect royalty income from Parker Labs in the US for its EPA-re
17 Oct 2018
FY 2018 results – US update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY 2018 results – US update
Tristel Plc (TSTL:LON) | 462 34.7 1.6% | Mkt Cap: 219.8m
- Published:
17 Oct 2018 -
Author:
Mark Brewer -
Pages:
16
Full-year results were marginally ahead of the July trading update. Revenue growth (10%), albeit at the lower end of target range, was affected by lower UK growth (+1%) but international markets (+19%) now account for 51% of revenues and EBITDA rose 16%. Clarity from the US FDA with regards the regulatory process for a high-level disinfectant has been received, and the revised process will delay the filing by six months. We still expect royalty income from Parker Labs in the US for its EPA-re